DSM-Firmenich stock: Results are due November 4 after EUR 4.66 billion first-half revenue

Published on 10/21/2026 at 17:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The first-half margin reached 19.50 percent. DSM-Firmenich stock costs EUR 107.75 on October 21, 2026, up 0.23 percent versus the Xetra close.

Reporting date November 4

DSM-Firmenich will report its next results on November 4, 2026.
Continuing-operations revenue reached EUR 4.66 billion in the first half of 2026, with a 19.30 percent adjusted EBITDA margin.
DSM-Firmenich stock costs EUR 107.75 at Lang & Schwarz on October 21, 2026 at 5:01 p.m. CEST, 0.23 percent above the Xetra close of October 20, 2026.

Fotorealistisches Duftlabor mit Wissenschaftlern und Destillationsanlagen — dsm-firmenich AG (ISIN CH1216478797) betreibt moderne Duftlabore mit Wissenschaftlern und Analysegeräten für Aromastoffe, Illustration mit AI erstellt.

DSM-Firmenich will report its next results on November 4, 2026, according to The Wall Street Journal. The date follows first-half 2026 continuing-operations revenue of EUR 4.66 billion, up 5.00 percent on an organic basis, as reported by De Belegger. DSM-Firmenich stock was trading at EUR 107.75 at Lang & Schwarz on October 21, 2026 at 5:01 p.m. CEST, up 0.23 percent versus the Xetra close of October 20, 2026 at EUR 107.50.

Margin reaches 19.30 percent

The first-half continuing-operations revenue of EUR 4.66 billion produced adjusted earnings before interest, taxes, depreciation and amortization of EUR 900.00 million, equal to a 19.30 percent margin. In the second quarter, the adjusted margin reached 19.50 percent, 0.40 percentage points above the first quarter, according to De Belegger.

Stock stays below the yearly high

The EUR 107.75 Lang & Schwarz price sits EUR 2.10 below the 52-week high of EUR 109.85 and EUR 52.53 above the 52-week low of EUR 55.22, both as of October 21, 2026. The session volume was 128,342 shares, while the market capitalization stood at EUR 26.3 billion. The stock was up 56.34 percent since the start of 2026 in the Euronext Amsterdam quote.

What does valuation imply?

BNP Paribas downgraded DSM-Firmenich to Neutral from Outperform and set a EUR 100.00 target on October 2, 2026, according to Business Insider. The cited target lies 7.19 percent below the Lang & Schwarz price. The same report said Citi raised its target from EUR 106.00 to EUR 111.00, putting that target 3.02 percent above the current euro price.

Peer comparison

DSM-Firmenich: up 0.23 percent versus the Xetra close, market capitalization EUR 26.3 billion. The available market figures place the company in specialty chemicals, with nutrition, health and beauty solutions as its main operating areas.

Trading level and next date

The immediate market question is whether the November 4 results can clarify the distance between a 19.50 percent quarterly margin and the company outlook for an adjusted margin of about 20 percent in 2026. The first-half adjusted earnings per share reached EUR 1.84, up 14.00 percent from the prior-year period, according to De Belegger.

Stock holds above EUR 107

The share price remained close to its 52-week high during the October 21 session, while the next scheduled results date provides the next clear reporting marker. The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.